A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma-Reference-Cited by-同舟云学术

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma

Published:2024-09 Issue:5 Volume:19 Page:723-733
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Gong Jifang,Guo Ye,Zhang Yanqiao,Ba Yi,Chen Tong,Li Wei,Zhou Caicun,Wang Mengzhao,Yang Haiyan,Zhou Yuhong,Cai Qiqing,Wang Ziping,Huang Gang,Zhang Wei,Su Rila,Cai Zhongheng,Yue Zenglian,Dou Jinzhou,Li Peiqi,Wu Rachel,Tse Archie N.,Shen Lin^ORCID

Funder

CStone Pharmaceuticals Co. Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01091-8.pdf

Reference26 articles.

1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.

2. Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–204.

3. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362: k3529.

4. Ye J, Ji X, Dennis PA, Abdullah H, Mukhopadhyay P. Relationship between progression-free survival, objective response rate, and overall survival in clinical trials of PD-1/PD-L1 immune checkpoint blockade: a meta-analysis. Clin Pharmacol Ther. 2020;108(6):1274–88.

5. Zhao Y, Liu L, Weng L. Comparisons of underlying mechanisms, clinical efficacy and safety between anti-PD-1 and anti-PD-L1 immunotherapy: the state-of-the-art review and future perspectives. Front Pharmacol. 2021;12: 714483.